Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 2;16(1):1132.
doi: 10.1186/s12889-016-3784-4.

The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy

Fabio Mesquita  1 , Melina Erica Santos  1 , Adele Benzaken  1 , Renato Girade Corrêa  1 , Elisa Cattapan  1 , Leandro Soares Sereno  2 , Marcelo Contardo Moscoso Naveira  3
Affiliations

The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy

Fabio Mesquita et al. BMC Public Health. .

Abstract

Background: Hepatitis C affects over 185 million people around the world. This silent disease is responsible for up to 700,000 deaths per year. Despite the scientific revolution in diagnosis and treatment, hepatitis C control remains a huge challenge due to the cost of effective medications. In response to the global outcry of hepatitis epidemic and the need to improve the nation's public health response, the Ministry of Health of Brazil revolutionized hepatitis C treatment by incorporating highly effective drugs that can be accessed through sustainable and universal means.

Discussion: This paper describes the unique process of implementing evidence-informed policy to respond to hepatitis C epidemic through the update of hepatitis C treatment in Brazil based on the estimate of disease prevalence, current international guidelines, and the cost-effectiveness impact in the Brazilian Unified Health System. Through a debate of an experience report, the authors underlie the strategic plan implemented according to the situation analysis that emphasized the need to improve its current response over a relatively short-term period. The comprehensive response is detailed comprising three main objectives: improve treatment outcomes by evaluating and incorporating new and effective medications at a sustainable price; elaborate on clinical guidelines to treat hepatitis C patients; and develop awareness and diagnosis campaigns targeted at the population of interest. In this scenario, Brazil was able to obtain an unprecedented discount for a high-medium income country; provided treatment to more than 7000 individuals in the last 2 months of 2015; and expects to treat 38,000 new patients in 2016. The remarkable process applied in Brazil was developed according to epidemiological data and scientific evidence, and it was motivated by the engagement of the country in the Sustainable Development Goals, which may inspire other developing countries to identify ways to achieve these goals by 2030.

Keywords: Health access; Hepatitis C; Interferon-free.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hepatitis C cases according to age and gender, Brazil, 2008–2014
Fig. 2
Fig. 2
Hospitalizations, deaths and case fatality rates due to liver cancer, Brazil, 2008–2014
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention. Viral Hepatitis–Hepatitis C Information [Internet]. 2016. Available from: http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Cited 9 Jun 2016.
    1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect [Internet]. European Society of Clinical Infectious Diseases; 2011;17(2):107–15. Available from: http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x. - DOI - PubMed
    1. Lancet T. Hepatitis C: only a step away from elimination? Lancet [Internet]. Elsevier Ltd; 2015;385(9973):1045. Available from: http://dx.doi.org/10.1016/S0140-6736(15)60584-0. - DOI - PubMed
    1. Naveira M, Barbosa J, Sereno L, Domanico A, Mesquita F, de Souza LA. 12 years of universal access to hepatitis C treatment: Brazil’s comprehensive response. J Int Assoc Provid AIDS Care. 2014;13(6):560–567. doi: 10.1177/2325957414547739. - DOI - PubMed
    1. Dieterich D, Bacon B, Flamm S, Kowdley K, Milligan S, Tsai N, Younossi Z, Lawitz E. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network–Academic and community treatment of a real-world, heterogeneous population [Internet]. 2014. Available from: http://www.natap.org/2014/AASLD/AASLD_09.htm. Accessed 9 June 2016.

Publication types

Substances